AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38926732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) treatment
Number of subjects: 63
Study 38926732 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1 cell polarization
Number of subjects: 63
Study 38926732 — intervention group
Group type: EXPERIMENTAL
Intervention: LCN2 and KDM5D genes
Number of subjects: 63
Study 38926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Adappt application (positive psychology and mindfulness-based app)
Number of subjects: 212
Study 38926739 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 212
Study 38926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Adappt application
Number of subjects: 212
Study 38926753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD (females)
Number of subjects: 177
Study 38926753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD (males)
Number of subjects: 177
Study 38926753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low LDL-c and CAD (males)
Number of subjects: 177
Study 38926753 — intervention group
Group type: COMPARATOR
Intervention: Patients without CAD (females)
Number of subjects: 177
Study 38926753 — intervention group
Group type: COMPARATOR
Intervention: Patients without CAD (males)
Number of subjects: 177
Study 38926810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Best Practices (TBP)
Number of subjects: 415
Study 38926810 — intervention group
Group type: COMPARATOR
Intervention: General Best Practices (GBP)
Number of subjects: 415
Study 38926901 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, 3 times per week, duration ranging from 30 to 45 minutes over 4 months.
Number of subjects: 28
Study 38926901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 28
Study 38926908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who received a waiver (pW)
Number of subjects: 1019
Study 38926908 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive a waiver (pNW)
Number of subjects: 1019
Study 38927068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester beverage delivering β-hydroxybutyrate (KEβHB)
Number of subjects: 0
Study 38927068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38927884 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoKnife System (IRE)
Number of subjects: 121
Study 38927991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 207
Study 38927991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab+Ipilimumab boosts
Number of subjects: 207
Study 38929215 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Mediterranean diet (MD) plans delivered via a clinical decision support system (CDSS) every 15 days
Number of subjects: 40
Study 38929215 — intervention group
Group type: COMPARATOR
Intervention: General nutritional advice (Control)
Number of subjects: 40
Study 38930117 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38931260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of DMB (150 mg DMB/tablet)
Number of subjects: 31
Study 38931260 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of DMB (300 mg DMB/tablet)
Number of subjects: 31
Study 38931260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg freeze-dried strawberry)
Number of subjects: 31
Study 38931864 — intervention group
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer vaccine candidate
Number of subjects: 0
Study 38931864 — intervention group
Group type: COMPARATOR
Intervention: Purified products from 1 L scale
Number of subjects: 0
Study 38932417 — intervention group
Group type: EXPERIMENTAL
Intervention: L2-based target antigen (LBTA) vaccination
Number of subjects: 0
Study 38932417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38932575 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543
Study 38932575 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14543
Study 38932583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg meglumine or 61 mg free acid)
Number of subjects: 348
Study 38932583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 38932589 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 1000
Study 38932589 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 1000
Study 38932723 — intervention group
Group type: EXPERIMENTAL
Intervention: Padsevonil
Number of subjects: 0
Study 38933370 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Exercise Programmes (IPEPs)
Number of subjects: 514
Study 38933603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least a single documented adverse event (AE)
Number of subjects: 1490
Study 38933603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple adverse events (>1 AE)
Number of subjects: 1490
Study 38933603 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall documented adverse events (AEs)
Number of subjects: 1490
Study 38934093 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + Ipilimumab (I) and/or Nivolumab (N)
Number of subjects: 54
Study 38934093 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + Nivolumab (N) and Brentuximab vedotin (BV) + Ipilimumab (I) + Nivolumab (N)
Number of subjects: 54
Study 38934093 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV) + Ipilimumab (I)
Number of subjects: 54
Study 38934093 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline or after one treatment cycle
Number of subjects: 54
Study 38934112 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV-based cfPWV measurement
Number of subjects: 100
Study 38934112 — intervention group
Group type: COMPARATOR
Intervention: Applanation tonometry (Sphygmocor)
Number of subjects: 100
Study 38934111 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted clinic-based intervention
Number of subjects: 1045
Study 38934111 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1045
Study 38934147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50-mg
Number of subjects: 718
Study 38934147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 10-mg
Number of subjects: 718
Study 38934147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 38934147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (any dose)
Number of subjects: 718
Study 38934147 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to Ritlecitinib
Number of subjects: 718
Study 38934229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CYP2B6 genotype (fast, intermediate, slow)
Number of subjects: 112
Study 38934229 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn CYP2B6 genotype (fast, intermediate, slow)
Number of subjects: 112
Study 38934229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and newborn efavirenz concentration correlation
Number of subjects: 112
Study 38934229 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn plasma-to-maternal plasma ratio
Number of subjects: 112
Study 38934229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord-to-maternal plasma ratio
Number of subjects: 112
Study 38934231 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHA-CMC(+) injections
Number of subjects: 175
Study 38934231 — intervention group
Group type: COMPARATOR
Intervention: Control/delayed treatment group
Number of subjects: 175
Study 38934517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (75 min/session, 3 times a week for 16 weeks)
Number of subjects: 46
Study 38934517 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 38934602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous unfractionated heparin (UFH) infusion at 10 to 15 units/kg/h for infants with CRT and 2 to 3 units/kg/h without CRT
Number of subjects: 35
Study 38934602 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 35
Study 38934602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous unfractionated heparin (UFH) infusion
Number of subjects: 35
Study 38934714 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 27
Study 38934799 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy alone
Number of subjects: 165
Study 38934799 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgical group
Number of subjects: 165
Study 38934845 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1010 (6.25 µg to 200 µg)
Number of subjects: 100
Study 38934845 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1010 (25 µg to 200 µg)
Number of subjects: 100
Study 38934845 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1010 (6.25 µg to 25 µg)
Number of subjects: 100
Study 38934845 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1010 (50 µg)
Number of subjects: 100
Study 38934845 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1010
Number of subjects: 100
Study 38934845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38934845 — intervention group
Group type: COMPARATOR
Intervention: Afluria
Number of subjects: 100
Study 38934914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession attentional bias modification (ABM) training, details on dosage and duration not specified
Number of subjects: 0
Study 38934914 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38934966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to intravenous furosemide regimen
Number of subjects: 230
Study 38934966 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to intravenous furosemide regimen
Number of subjects: 230
Study 38934964 — intervention group
Group type: EXPERIMENTAL
Intervention: Corvia Atrial Shunt
Number of subjects: 621
Study 38934964 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 621
Study 38934967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 38934967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 38934968 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injections
Number of subjects: 128
Study 38934968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 38935053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led brief behavioral treatment for insomnia (BBTI)
Number of subjects: 42
Study 38935053 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene group
Number of subjects: 42
Study 38935059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-test (1 mcg/kg fentanyl administration)
Number of subjects: 240
Study 38935059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-test (FRR > 53%)
Number of subjects: 240
Study 38935059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir pulse oxygen saturation
Number of subjects: 240
Study 38935059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-test (FRR)
Number of subjects: 240
Study 38935085 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation (EX)
Number of subjects: 71
Study 38935085 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 71
Study 38935125 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection and systemic treatment (PTR+SYST)
Number of subjects: 480
Study 38935125 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment only (SYST)
Number of subjects: 480
Study 38935202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 1045
Study 38935213 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose education and naloxone distribution (OEND) implementation in jails
Number of subjects: 0
Study 38935259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-species probiotic (Lactobacillus rhamnosus and Bifidobacterium lactis)
Number of subjects: 33
Study 38935373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 483
Study 38935373 — intervention group
Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiotherapy (3D-CRT)
Number of subjects: 483
Study 38935373 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 483
Study 38935373 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart V40 (<20%)
Number of subjects: 483
Study 38935373 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart V40 (≥20%)
Number of subjects: 483
Study 38935373 — intervention group
Group type: COMPARATOR
Intervention: IMRT and 3D-CRT
Number of subjects: 483
Study 38935379 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 304
Study 38935379 — intervention group
Group type: EXPERIMENTAL
Intervention: App group
Number of subjects: 304
Study 38935379 — intervention group
Group type: EXPERIMENTAL
Intervention: App plus feedback group
Number of subjects: 304
Study 38935400 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation with C-loop IOL
Number of subjects: 186
Study 38935400 — intervention group
Group type: COMPARATOR
Intervention: C-loop IOL only (control group)
Number of subjects: 186
Study 38935400 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation with C-loop IOL (in eyes with AL ≥30 mm)
Number of subjects: 186
Study 38935400 — intervention group
Group type: COMPARATOR
Intervention: C-loop IOL only (control group, in eyes with AL ≥30 mm)
Number of subjects: 186
Study 38935428 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program (SICP)
Number of subjects: 20
Study 38935496 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Speed Resistance Training (HSRT) for 16 weeks, 3 sessions per week, 60-70 minutes per session, 5-6 exercises, 2-3 sets, 6-10 reps/exercise
Number of subjects: 79
Study 38935496 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) did not perform any exercise training program
Number of subjects: 79
Study 38935839 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-mismatched allogeneic adoptive immune therapy (AAIT) in combination with ART
Number of subjects: 0
Study 38935839 — intervention group
Group type: COMPARATOR
Intervention: Conventional ART-only regimen
Number of subjects: 0
Study 38935923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab emtansine (T-DM1) for 1 year
Number of subjects: 187
Study 38935923 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH)
Number of subjects: 187
Study 38936378 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/VI with temsirolimus
Number of subjects: 297
Study 38936378 — intervention group
Group type: COMPARATOR
Intervention: VAC/VI alone
Number of subjects: 297
Study 38936379 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST (irinotecan-temozolomide and dasatinib-rapamycin)
Number of subjects: 129
Study 38936379 — intervention group
Group type: COMPARATOR
Intervention: Control (irinotecan-temozolomide)
Number of subjects: 129
Study 38936379 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST (in patients with amplified MYCN)
Number of subjects: 129
Study 38936379 — intervention group
Group type: COMPARATOR
Intervention: Control (in patients with amplified MYCN)
Number of subjects: 129
Study 38936379 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST (in patients without amplified MYCN)
Number of subjects: 129
Study 38936379 — intervention group
Group type: COMPARATOR
Intervention: Control (in patients without amplified MYCN)
Number of subjects: 129
Study 38936466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 50/25 µg once daily
Number of subjects: 902
Study 38936466 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 50 µg once daily
Number of subjects: 902
Study 38936469 — intervention group
Group type: EXPERIMENTAL
Intervention: Early venting within 24 hours of ECMO insertion
Number of subjects: 217
Study 38936469 — intervention group
Group type: COMPARATOR
Intervention: No or delayed unloading (venting)
Number of subjects: 217
Study 38936469 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not experiencing the primary outcome within 6 months
Number of subjects: 217
Study 38936548 — intervention group
Group type: EXPERIMENTAL
Intervention: Term SGA
Number of subjects: 1441
Study 38936548 — intervention group
Group type: COMPARATOR
Intervention: Term AGA
Number of subjects: 1441
Study 38936550 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice introduction <6 months
Number of subjects: 524
Study 38936550 — intervention group
Group type: COMPARATOR
Intervention: Juice introduction 6 to <12 months
Number of subjects: 524
Study 38936550 — intervention group
Group type: COMPARATOR
Intervention: Juice introduction ≥12 months
Number of subjects: 524
Study 38936652 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mild hypercapnia
Number of subjects: 125
Study 38936652 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia
Number of subjects: 125
Study 38936755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine 0.5 mg daily
Number of subjects: 7062
Study 38936755 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 7062
Study 38936755 — intervention group
Group type: COMPARATOR
Intervention: Placebo for colchicine
Number of subjects: 7062
Study 38936755 — intervention group
Group type: COMPARATOR
Intervention: Placebo for spironolactone
Number of subjects: 7062
Study 38937182 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose test group (2-1-1 regimen)
Number of subjects: 1800
Study 38937182 — intervention group
Group type: COMPARATOR
Intervention: Four-dose control group
Number of subjects: 1800
Study 38937182 — intervention group
Group type: COMPARATOR
Intervention: Five-dose control group
Number of subjects: 1800
Study 38937182 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose test group
Number of subjects: 1800
Study 38937298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant alone
Number of subjects: 0
Study 38937298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant in combination with taselisib (PI3K inhibitor)
Number of subjects: 0
Study 38937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) integration, monthly meetings with a palliative care team for 12 months
Number of subjects: 20
Study 38937331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 71
Study 38937331 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate (CH) content
Number of subjects: 71
Study 38937331 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein content
Number of subjects: 71
Study 38937331 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 71
Study 38937404 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg initial doses at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks or CZP 400 mg every 2 weeks maintenance dosing.
Number of subjects: 399
Study 38937404 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 399
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectability status (borderline versus resectable)
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectability status (locally advanced versus resectable)
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor location (head versus body/tail)
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular resection
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural invasion
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of positive lymph nodes
Number of subjects: 1693
Study 38937412 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection margin status (R1 < 1 mm versus R0 ≥ 1 mm)
Number of subjects: 1693
Study 38937446 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 41
Study 38937667 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based gait, balance, and resistance exercise intervention
Number of subjects: 0
Study 38937696 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational burnout assessment using Maslach Burnout Inventory (MBI-ES)
Number of subjects: 218
Study 38937696 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic, lifestyle, and work-related factors
Number of subjects: 218
Study 38937696 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching special needs students
Number of subjects: 218
Study 38937696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity and alcohol intake
Number of subjects: 218
Study 38937696 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, being married, language of teaching, having a disability, sub-optimal physical fitness, poor sleep quality, and ever smoking
Number of subjects: 218
Study 38937769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intervention
Number of subjects: 264
Study 38937769 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended intervention
Number of subjects: 264
Study 38937769 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 264
Study 38937776 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CET + CBT
Number of subjects: 156
Study 38937776 — intervention group
Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 156
Study 38937792 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 40
Study 38937792 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment of surgeon's choice
Number of subjects: 40